Nuclear medicine in head and neck oncology: Reality and perspectives

Journal of Nuclear Medicine

Volumn 40, Issue 1, 1999, Pages 91-95

  Chisin, Roland ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Fluorodeoxyglucose; Head and neck; PET; Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROID CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032926338     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Chisin R, Noyek AM, Israel O, Witterick IJ, Kirsh JC, Front D. Contribution of nuclear medicine to the diagnosis and management of extracranial head and neck diseases (excluding thyroid and parathyroid). Isr J Med Sci. 1992;28:254-261.
2. Vokes EE, Weichselbaum RR, Lippman SM, Kikong W. Head and neck cancer. N Engl J Med. 1993;328:184-194.
3. Boudreau RJ, Remley KB. Advances in imaging the thyroid and parathyroid glands: nuclear scintigraphy, computed tomography, and magnetic resonance imaging. Thyroid Today. 1996;19:1-16.
4. Gharib H. Management of thyroid modules: another look. Thyroid Today. 1997;20:1-11
5. Klain M, Maurea S, Cuoculo A, et al. Tc-99m tetrafosmin imaging in thyroid diseases. Comparison with Tc-99m pertechnetate, thallium-201 and Tc-99m methoxyisobutyl isonitrile scans. Eur J Nucl Med. 1996;23:1568-1574.
6. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312-319.
7. Davis JP, Maisey NM, Chevreton EB. Positron emission tomography; a useful imaging technique for otolaryngology, head and neck surgery? J Laryngol Otol. 1998;112:125-127.
8. Dorr U, Sautter-Bihl ML, Bihl H. The contribution of somatostatin-receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol. 1994;21:42-45.
9. Neumann DR, Esselstyn CB, Kim EY. Recurrent postoperative parathyroid carcinoma: FDG PET and sestamibi SPECT findings. J Nucl Med. 1996;37:2000-2001.
10. Keyes JW Jr, Watson NE, Williams DW, et al. FDG PET in head and neck cancer. AJR 1997;169:1663-1669.
11. Lapela M, Grenman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-(F-18)fluoro-2-deoxy-D-glucose. Radiology. 1995;197: 205-211.
12. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2(F18)fluoro-deoxyglucose PET and MR imaging diagnoses. Radiology. 1996;200:135-141.
13. McGuirt WF, Greven KM, Keyes JW Jr, et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngo. 1995;104:274-278.
14. Minn H, Aitasalo K, Happonen RP. Detection of cancer recurrence in irradiated mandible using positron emission tomography. Eur Arch Otorhinolaryngol. 1993;250:312-315.
15. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, Seifert E, Strauss LG. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg. 1995;121:272-276.
16. Greven KM, Williams DW 3rd, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355-1359.
17. Kado H, Ogawa T, Okudera T, Kanno I., Hatazawa J, Uemura K. Parapharyngeal meningioma extending from the intracranial space evaluated by FDG PET. J Nucl Med. 1998;39:302-304.
18. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
19. 11C) methionine. Int J Radiat Oncol Biol Phys. 1995;32:787-794.
20. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med. 1993;34:773-779.
21. Lindholm P, Leskinen S, Lapela M. Is tumor carbon-11-methionine uptake of prognosis value in squamous cell head and neck cancer? J Nucl Med. 1998;39: 1393-1397.
22. Braams JW, Pruim J, Nikkels PGJ, Roodenburg JLN, Vaalburg W, Vermey A. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. J Nucl Med. 1996;37:897-901.
23. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg. 1997;26: 112-115.
24. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol. 1997;22:209-214.
25. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
26. Uematsu H, Sadato N, Yonekura Y, et al Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. J Nucl Med. 1998;39:2121-2127.
27. 18F)fluoro-2-deoxy-D-glucose head and neck images. Am J Surg 1996;172: 628-632.
28. Chisin R, Pietrzyk U, Sichel JY, et al. Registration and display of multimodal images: applications in the extracranial head and neck region. J Otolaryngol. 1993;22:214-219.
29. Mukherji SK, Drane WE, Mancuso AA, Parsons JT, Mendenhall WM, Stringer S. Occult primary tumors of the head and neck: detection with 2-(F-18)fluoro-2-deoxy-D-glucose SPECT. Radiology. 1996;199:761-766.
30. Stokkel MP, Terhaard CH, Mertens IL, Hordijk G-J, Van Rijk PP. Fluorine-18-fluorodeoxyglucose detection of laryngeal cancer post radiotherapy using dual-head coincidence imaging. J Nucl Med. 1998;39:1385-1387.
31. Lauberbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinomas. J Nucl Med. 1995;36:1747-1757.
32. Olmos RAV, Balm AJM, Hilgers FJM, et al. Thallium-201 SPECT in the diagnosis of head and reck cancer. J Nucl Med 1997;38:873-879.
33. Kostaglu L, Uysal U, Ozyar E, et al. Pre- and post-therapy thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma. J Nucl Med. 1996;37:1962-1964.
34. Chan KM, Merrick MV, Mitchell R. Bone SPECT to assess mandibular invasion by intraoral squamous cell carcinomas. J Nucl Med. 1996;37:42-45.
35. Leitha T, Glaser C, Pruckmayer M, et al. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion. J Nucl Med. 1998;39:1166-1171.
36. Fukomoto M, Yoshida S, Yoshida D, Kishimoto S. Dual-isotope SPECT of skull-base invasion of head and neck tumors. J Nucl Med. 1995;36:1740-1746.
37. Ampil FL, Wood MJ, Chin HW, Hoasjoe DK, Aarslad RF, Hilton DL. Screening bone scintigraphy in the staging of locally advanced head and neck cancer. J Craniomaxillofac Surg. 1995;23:115-118.
38. Keyes JW Jr, Harkness BA, Greven KM, Williams DW III, Watson NE Jr, McGuirt WF. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99-102.
39. O'Brien CJ, Uren RF, Thompson JF, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg. 1995;170:461-466.
40. 18FDG imaging in the clinical evaluation of head and neck lymphoma. Clin Oncol R Coll Radiol. 1996;8:51-54.
41. Hansman Whiteman ML, Serafini AN, Telischi FF, Civantos JC, Falcone S. III-In octreotide scintigraphy in the evaluation of head and neck lesions. Am J Neuroradiol. 1997;18:1073-1080.
42. Reuland P, Overkamp D, Aicher KP, Bien S, Müller-Schauenburg W, Feine U. Catecholamine secreting glomus tumor detected by iodine-123-MIBG scintigraphy. J Nud Med. 1996;37:463-465.
43. Mancuso AA, Drane WE, Mukherji SK. The promise of FDG in diagnosis and surveillance of head and neck cancer. Cancer. 1994;74:1193-1195.